Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCorp RxTSXV:PCRX 35 EV-to-EBIT is -84.67 as of Aug. 12, 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 473 Healthcare Providers & Services companies, PharmaCorp Rx ranks worse than 211416.28% on this metric.
The historical rank and industry rank for PharmaCorp Rx's EV-to-EBIT or its related term are showing as below:
TSXV:PCRX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -293.54 Med: -58.85 Max: 151.5
Current: -84.67
During the past 5 years, the highest EV-to-EBIT of PharmaCorp Rx was 151.50. The lowest was -293.54. And the median was -58.85.
TSXV:PCRX's EV-to-EBIT is ranked worse than 100% of 473
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs TSXV:PCRX: -84.67
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PharmaCorp Rx's Enterprise Value for the quarter that ended in Mar. 2026 was C$57.25 Mil.
PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx EV-to-EBIT Related Terms
PharmaCorp Rx EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for PharmaCorp Rx's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's EV-to-EBIT falls into.
PharmaCorp Rx's current Enterprise Value is C$79.84 Mil.
PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a EV-to-EBIT of -84.67 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #999999 out of 473 companies in the Healthcare Providers & Services industry.
Is PharmaCorp Rx's EV-to-EBIT too high?
PharmaCorp Rx's current EV-to-EBIT is -84.67. Based on the distribution chart, PharmaCorp Rx ranks #999999 out of 473 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmaCorp Rx has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #999999 out of 473 companies for EV-to-EBIT. This places PharmaCorp Rx in the lower half of its industry. The industry median EV-to-EBIT is 15.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PharmaCorp Rx and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current EV-to-EBIT is -84.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current EV-to-EBIT of -84.67. The current EV-to-EBIT is -84.67. PharmaCorp Rx's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current EV-to-EBIT is -84.67 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
35GF Score
Get the complete analysis for TSXV:PCRX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
